We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
Read MoreHide Full Article
We expect Fusion Pharmaceuticals to beat expectations when it reports first-quarter 2024 results. Without a marketed product, investors will focus on the upcoming earnings call for updates regarding Fusion’s pipeline candidates.
In March 2024, Fusion signed a definitive agreement with AstraZeneca (AZN - Free Report) , where the latter will acquire all outstanding shares of FUSN for $21 per share in cash, aggregating to $2 billion.The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions and clearance from regulatory authorities.
Let's see how things might have shaped up in the to-be-reported quarter.
Factors to Consider
Fusion makes next-generation radiopharmaceuticals as precision medicines. It has a diversified pipeline of targeted alpha therapy (TAT) programs.
The company’s lead product candidate, FPI-2265, is a small molecule-based TAT targeting prostate-specific membrane antigen to treat cancer.
In January 2024, Fusion announced that it has aligned with the FDA regarding the phase II/III study protocols for FPI-2265 in previously treated metastatic castration-resistant prostate cancer (mCRPC) patients. The phase II dose-optimization portion of the study is expected to begin in the second quarter of 2024.
Subject to positive results from the mid-stage portion of the study and upon reaching alignment with the FDA regarding the recommended late-stage dosing strength, the company anticipates initiating the phase III global registrational study in 2025. Further updates regarding the planned mid to late-stage mCRPC study are expected in the first-quarter earnings release.
The company has two other candidates, FPI-1434 and FPI-2059, which are currently being developed in separate early-stage studies for patients with solid tumors expressing IGF-1R and NTSR1, respectively.
Fusion reported positive initial findings from the phase I study of FPI-1434 in January 2024. The company is likely to share further updates from the study in mid-2024.
FUSN has a collaboration with AstraZenecato jointly develop novel TATs and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Response Inhibitors and immuno-oncology agents. Its revenues comprise periodic collaboration revenues from its partnership with AZN.
Currently, Fusion and AstraZeneca are jointly developing FPI-2068, a bispecific IgG-based TAT, in an early-stage study for solid tumor indications expressing EGFR-cMET, which include head and neck squamous cell carcinoma, non-small cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma.
Fusion expects to initiate a combination study of FPI-2265 plus Merck (MRK - Free Report) /AstraZeneca’s Lynparza (Olaparib) in earlier lines of mCRPC treatment in the first half of 2024.
The company has collaborated with Merck to evaluate FPI-1434 in combination with the latter’s blockbuster PD-L1 inhibitor, Keytruda, in patients with solid tumors expressing IGF-1R. The company is expected to provide an update regarding the same in the upcoming earnings release.
Earnings Surprise History
The company’s earnings surpassed estimates in two of the trailing four quarters and missed on the other two occasions, delivering an average negative surprise of 7.46%.
Year to date, shares of FUSN have skyrocketed 122.7% against the industry’s 12% decline.
Image Source: Zacks Investment Research
Earnings Whisper
Our proven model predicts an earnings beat for Fusion this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat, which is the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Fusion has an Earnings ESP of +0.34%. The Zacks Consensus Estimate for earnings is currently pegged at 37 cents.
Zacks Rank: FUSN currently carries a Zacks Rank #3.
Fusion Pharmaceuticals Inc. Price and EPS Surprise
Here is another stock worth considering from the healthcare space, as our model shows that it has the right combination of elements to beat on earnings this reporting cycle.
Shares of Sarepta Therapeutics have gained 32.1% in the year-to-date period. SRPT’s earnings beat estimates in each of the last four quarters, delivering an average surprise of 464.56%.
Image: Bigstock
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
We expect Fusion Pharmaceuticals to beat expectations when it reports first-quarter 2024 results. Without a marketed product, investors will focus on the upcoming earnings call for updates regarding Fusion’s pipeline candidates.
In March 2024, Fusion signed a definitive agreement with AstraZeneca (AZN - Free Report) , where the latter will acquire all outstanding shares of FUSN for $21 per share in cash, aggregating to $2 billion.The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions and clearance from regulatory authorities.
Let's see how things might have shaped up in the to-be-reported quarter.
Factors to Consider
Fusion makes next-generation radiopharmaceuticals as precision medicines. It has a diversified pipeline of targeted alpha therapy (TAT) programs.
The company’s lead product candidate, FPI-2265, is a small molecule-based TAT targeting prostate-specific membrane antigen to treat cancer.
In January 2024, Fusion announced that it has aligned with the FDA regarding the phase II/III study protocols for FPI-2265 in previously treated metastatic castration-resistant prostate cancer (mCRPC) patients. The phase II dose-optimization portion of the study is expected to begin in the second quarter of 2024.
Subject to positive results from the mid-stage portion of the study and upon reaching alignment with the FDA regarding the recommended late-stage dosing strength, the company anticipates initiating the phase III global registrational study in 2025. Further updates regarding the planned mid to late-stage mCRPC study are expected in the first-quarter earnings release.
The company has two other candidates, FPI-1434 and FPI-2059, which are currently being developed in separate early-stage studies for patients with solid tumors expressing IGF-1R and NTSR1, respectively.
Fusion reported positive initial findings from the phase I study of FPI-1434 in January 2024. The company is likely to share further updates from the study in mid-2024.
FUSN has a collaboration with AstraZenecato jointly develop novel TATs and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Response Inhibitors and immuno-oncology agents. Its revenues comprise periodic collaboration revenues from its partnership with AZN.
Currently, Fusion and AstraZeneca are jointly developing FPI-2068, a bispecific IgG-based TAT, in an early-stage study for solid tumor indications expressing EGFR-cMET, which include head and neck squamous cell carcinoma, non-small cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma.
Fusion expects to initiate a combination study of FPI-2265 plus Merck (MRK - Free Report) /AstraZeneca’s Lynparza (Olaparib) in earlier lines of mCRPC treatment in the first half of 2024.
The company has collaborated with Merck to evaluate FPI-1434 in combination with the latter’s blockbuster PD-L1 inhibitor, Keytruda, in patients with solid tumors expressing IGF-1R. The company is expected to provide an update regarding the same in the upcoming earnings release.
Earnings Surprise History
The company’s earnings surpassed estimates in two of the trailing four quarters and missed on the other two occasions, delivering an average negative surprise of 7.46%.
Year to date, shares of FUSN have skyrocketed 122.7% against the industry’s 12% decline.
Image Source: Zacks Investment Research
Earnings Whisper
Our proven model predicts an earnings beat for Fusion this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat, which is the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Fusion has an Earnings ESP of +0.34%. The Zacks Consensus Estimate for earnings is currently pegged at 37 cents.
Zacks Rank: FUSN currently carries a Zacks Rank #3.
Fusion Pharmaceuticals Inc. Price and EPS Surprise
Fusion Pharmaceuticals Inc. price-eps-surprise | Fusion Pharmaceuticals Inc. Quote
Other Stock to Consider
Here is another stock worth considering from the healthcare space, as our model shows that it has the right combination of elements to beat on earnings this reporting cycle.
Sarepta Therapeutics (SRPT - Free Report) has an Earnings ESP of +108.99% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Shares of Sarepta Therapeutics have gained 32.1% in the year-to-date period. SRPT’s earnings beat estimates in each of the last four quarters, delivering an average surprise of 464.56%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.